Last reviewed · How we verify
EN001
At a glance
| Generic name | EN001 |
|---|---|
| Also known as | EN001(Allogeneic early-passage Wharton's jelly-derived mesenchymal stem cells(WJ-MSCs) ), EN001 (Allogeneic early-passage Wharton's jelly-derived mesenchymal stem cells), EN001 (allogeneic umbilical cord-derived mesenchymal stem cells), EN001(allogenic early-passage mesenchymal stem cells derived from Wharton's jelly (WJ-MSCs) ) |
| Sponsor | ENCell |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Evaluate the Safety and Potential Efficacy of Human Wharton's Jelly-derived Mesenchymal Stem Cells With Charcot-Marie-Tooth Disease Type 1E (NA)
- Evaluate the Safety and Efficacy of EN001 in Patients With Charcot-Marie-Tooth Disease Type 1A (PHASE1)
- Determine the Safety and Dose of EN001 in Patients With Duchenne Muscular Dystrophy(DMD) (PHASE1)
- Evaluate the Efficacy and Safety of EN001 in Patients With Duchenne Muscular Dystrophy (PHASE1, PHASE2)
- Determine the Safety and Dose of EN001 in Patients With Charcot-Marie-Tooth Disease (CMT) Type 1A (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EN001 CI brief — competitive landscape report
- EN001 updates RSS · CI watch RSS
- ENCell portfolio CI